ABSTRACT
An example of a cost-eectiveness analysis, based on the results of the Scandinavian Simvastatin Survival Study9 (see Case study 1.4.1 in Chapter 1.4) is shown in Case study 5.2.1.10 is shows the so-called ‘base case’ incremental cost-eectiveness ratio to be US$ 6768. e most signicant assumptions used in reaching this estimate are indicated in the case study 5.2.1 but include:
■ projecting life expectancy at the end of the trial (the mean follow-up in the trial was 5.4 years) to ten years;
T he
ra pe
ut ic
s, e
vi de
nc e
an d
de ci
si on
-m ak
in g
■ no additional costs for monitoring and o ce visits; ■ the discount rate.
